BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 21518375)

  • 1. Effect of cytochrome P450 3A4 inhibitor ketoconazole on risperidone pharmacokinetics in healthy volunteers.
    Mahatthanatrakul W; Sriwiriyajan S; Ridtitid W; Boonleang J; Wongnawa M; Rujimamahasan N; Pipatrattanaseree W
    J Clin Pharm Ther; 2012 Apr; 37(2):221-5. PubMed ID: 21518375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
    Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.
    Mahatthanatrakul W; Nontaput T; Ridtitid W; Wongnawa M; Sunbhanich M
    J Clin Pharm Ther; 2007 Apr; 32(2):161-7. PubMed ID: 17381666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4.
    Fang J; Bourin M; Baker GB
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Feb; 359(2):147-51. PubMed ID: 10048600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
    Shin KH; Kim BH; Kim TE; Kim JW; Yi S; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2009 Dec; 31(12):3009-20. PubMed ID: 20110038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
    Shaik MN; LaBadie RR; Rudin D; Levin WJ
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
    Vermeulen A; Piotrovsky V; Ludwig EA
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.
    Troost J; Tatami S; Tsuda Y; Mattheus M; Mehlburger L; Wein M; Michel MC
    Br J Clin Pharmacol; 2011 Aug; 72(2):247-56. PubMed ID: 21496064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults.
    Darwish M; Bond M; Yang R; Hellriegel ET; Robertson P
    Clin Drug Investig; 2015 Nov; 35(11):725-33. PubMed ID: 26387027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
    Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
    Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders.
    Aman MG; Vinks AA; Remmerie B; Mannaert E; Ramadan Y; Masty J; Lindsay RL; Malone K
    Clin Ther; 2007 Jul; 29(7):1476-86. PubMed ID: 17825699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics and bioequivalence of two tablet formulations of 2 mg risperidone in healthy Thai male volunteers.
    Khorana N; Maphanta S; Lohitnavy O; Srichaiya A; Sayasathid J
    Int J Clin Pharmacol Ther; 2011 Jun; 49(6):409-14. PubMed ID: 21612749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.
    Yoo HD; Cho HY; Lee SN; Yoon H; Lee YB
    J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):329-41. PubMed ID: 22623266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety.
    Xiang Q; Zhao X; Zhou Y; Duan JL; Cui YM
    J Clin Pharmacol; 2010 Jun; 50(6):659-66. PubMed ID: 20332423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.